NCT02258334View on ClinicalTrials.gov

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® Quadrivalent vaccine, 2014-2015 formulation

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone I®ntradermal vaccine, 2014-2015 formulation

0.1 mL, Intradermal

BIOLOGICAL

Fluzone® Quadrivalent vaccine, 2014-2015 formulation

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone High Dose vaccine, 2014-2015 formulation

0.5 mL, Intramuscular

Trial Locations (4)

45249

Cincinnati

51503

Council Bluffs

70006

Metairie

95405

Santa Rosa

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02258334 - Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults | Biotech Hunter | Biotech Hunter